^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    XZP-5809

    i
    Other names: XZP-5809, XZP-5809-TT1
    Associations

    News

    Trials
    Company:
    Sihuan Pharmaceutical
    Drug class:
    EGFR inhibitor
    Related drugs:
    Associations

    News

    Trials
    over1year
    XZP-5809-TT1 Tablets in Patients With T790M Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=21, Terminated, Sihuan Pharmaceutical Holdings Group Ltd. | N=90 --> 21 | Trial completion date: Sep 2022 --> Apr 2022 | Recruiting --> Terminated; Strategic considerations
    Enrollment change • Trial completion date • Trial termination • Metastases
    |
    EGFR mutation • EGFR L858R • EGFR T790M
    |
    XZP-5809